MEDIGENA
Turnover is estimated at about €200,000, probably between €150,000 and €250,000. The micro format does not state turnover.
Balance sheet
balance sheet total €488,155 on 31-12-2025in euro
in euro
Position in the sector
6.1%
Higher than 11% of the 21,373 companies filing micro accounts in human health (NACE 86) in 2025.
0.79
Higher than 12% of the 20,922 companies filing micro accounts in human health (NACE 86) in 2025.
2.9%
Higher than 12% of the 21,223 companies filing micro accounts in human health (NACE 86) in 2025.
Net result: bottom quarter · Equity: bottom quarter · Balance sheet total: middle half · Working capital: bottom quarter
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 20236 months |
|---|---|---|---|---|
| 88,356 | 119,368 | 40,572 | ||
| 71,102 | 102,647 | 35,381 | ||
| 12,856 | 131,623 | 405,000 | ||
| -5,255 | -31,576 | - | ||
| -17,103 | -9,304 | 14,530 | ||
| 6.1% | 6.3% | 7.0% | ||
| 0.79 | 0.92 | 1.27 | ||
| 15.27 | 14.84 | 13.21 | ||
| 47.9% | 150.4% | 45.1% | ||
| 2.9% | 9.5% | 3.2% | ||
| 5.12 | 7.14 | 8.99 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 20236 months |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
488,155 | 569,190 | 452,828 | |
21/28 |
423,169 | 467,035 | 383,995 | |
21 |
299,836 | 339,836 | 379,836 | |
22/27 |
123,333 | 127,200 | 4,160 | |
24 |
108,301 | 110,410 | 4,160 | |
26 |
15,032 | 16,789 | - | |
29/58 |
64,986 | 102,155 | 68,833 | |
40/41 |
36,410 | 68,324 | 3,426 | |
40 |
- | 0 | 91 | |
41 |
36,410 | 68,324 | 3,335 | |
54/58 |
28,576 | 33,831 | 65,407 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
488,155 | 569,190 | 452,828 | |
10/15 |
30,000 | 35,940 | 31,876 | |
10/11 |
30,000 | 30,000 | 30,000 | |
14 |
0 | 5,940 | 1,876 | |
17/49 |
458,155 | 533,250 | 420,953 | |
17 |
369,236 | 415,006 | 362,529 | |
170/4 |
369,236 | 415,006 | 362,529 | |
42/48 |
82,090 | 111,460 | 54,303 | |
42 |
45,770 | 44,048 | 34,141 | |
44 |
15,742 | 17,412 | 1,230 | |
440/4 |
15,742 | 17,412 | 1,230 | |
45 |
- | 0 | 680 | |
450/3 |
- | 0 | 680 | |
47/48 |
20,578 | 50,000 | 18,253 | |
492/3 |
6,829 | 6,784 | 4,120 | |
| Income statement | ||||
9900 |
88,886 | 120,045 | 41,007 | |
630 |
56,723 | 48,583 | 21,005 | |
640/8 |
530 | 677 | 434 | |
9901 |
31,633 | 70,785 | 19,568 | |
65/66B |
17,254 | 16,721 | 4,512 | |
65 |
17,254 | 16,721 | 4,512 | |
9903 |
14,379 | 54,065 | 15,056 | |
67/77 |
- | 0 | 680 | |
9904 |
14,379 | 54,065 | 14,376 | |
9905 |
14,379 | 54,065 | 14,376 | |
| Appropriation of the result | ||||
9906 |
20,320 | 55,940 | 14,376 | |
14P |
5,940 | 1,876 | - | |
694/7 |
20,320 | 50,000 | 12,500 | |
694 |
11,840 | - | - | |
695 |
8,480 | 50,000 | 12,500 | |
| Document | ||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 09-08-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankThe accounts were filed on 09-08-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00391430.
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Tangible fixed assets | €12,856 | €131,623 | €5,000 |
| Intangible fixed assets | - | - | €400,000 |
| €56,723 | €48,583 | €21,005 |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on MEDIGENA
The operating result for 2025 is 55% lower than in 2024.
Debt's share of the balance-sheet total rises from 93.7% to 93.9%. Equity and debt are lower.